Caroline Litchfield, serving as EVP & CFO of Merck & Co Inc (NYSE: MRK), conducted a sale of 38,291 shares of the company on February 14, 2024, as disclosed in a recent filing with the SEC. On the day of the insider’s most recent sale, Merck & Co. Inc. shares were valued at $125.5, translating to a market capitalization of $320,655.281 billion.
An examination of Merck & Co. Inc.’s insider transaction history unveils a prevailing pattern of insider activity, with 19 sales recorded against merely one purchase over the preceding year. The past year witnessed consistent insider selling activity by Litchfield, amounting to a total of 38,291 shares, without any corresponding purchases, indicating a continued disposition of holdings by the insider.
Merck & Co. Inc., a renowned global healthcare entity, extends health solutions encompassing prescription medicines, vaccines, biologic therapies, and animal health products. Established in 1891, the company is headquartered in Kenilworth, New Jersey.
Have you read?
The World’s Largest Companies by Market Cap, 2024.
The World’s Richest Female Billionaires, 2024.
Revealed: Countries in the world with the most female billionaires, 2024.
Poorest Countries in the World, 2024.
Ranked: Discover the Most Popular Sports in the United States, 2024.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Thank you for supporting our journalism. Subscribe here.
For media queries, please contact: info@ceoworld.biz